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We explored how often journal articles reporting HIV research sponsored by a developed country,
but conducted in a developing country, mention research ethics committee (REC) approval from
both countries, and what factors are involved. Of all such 2007 articles on Medline conducted in
one of four developing countries (N = 154), only 52% mentioned such dual approval. Mention of
dual vs. single approval was more likely among articles with ≥ 50% sponsor country authors, and
the United States as the sponsor country. Also, dual approval was more likely among articles that
mentioned informed consent and funding, had ≥ 50% sponsor country authors, were biomedical
(vs. psychosocial), and appeared in journals adopting International Committee Medical Journal
Editors (ICMJE) guidelines. Dual approval was thus obtained in only half of the articles and was
associated with ethical and logistic issues, indicating the need for clearer and more universally
accepted guidelines.
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Research that is sponsored by the developed world and conducted in the developing world is
often reviewed by a research ethics committee (REC) or Institutional Review Board (IRB) in
each country, but such dual review poses numerous critical questions, and has received little,
if any, scholarly attention. Importantly, how often and under what circumstances such dual
review occurs and/or is reported is unknown.
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The amount of medical research carried out in developing countries continues to expand. In
2005, more than 20% of all clinical investigations submitted to the U.S. Food & Drug
Administration (FDA) took place outside of the U.S. and Western Europe (Tufts Center for
the Study of Drug Development, 2007). In 2006, 41% of active FDA-regulated principal
investigators (PIs) were based outside the U.S. (Getz, 2007), and in 2007, 56% of industry-
funded phase III clinical trials listed on clinicaltrials.gov were based outside the U.S.
(Glickman et al., 2009). This may reflect global health needs, and/or allow investigators to
obtain larger numbers of participants for studies while lowering costs (Schmit, 2005).
Despite this increase in research in the developing world, however, the reporting of ethical
protections in these situations in published reports of these studies is only beginning to
receive attention (Emanuel et al., 2004; Kass, Dawson, & Loyo-Berrios, 2003; Shapiro &
Meslin, 2001). In particular, while documentation of REC approval (note that we use the
term “REC” below to refer to both RECs and IRBs) is seen as the “final check in ensuring
the highest scientific and ethical standards, and a necessary step in protecting research
subjects and maintaining public trust” (Myles & Tan, 2003, p. 1212), only a few
investigations have examined the practice of ethics review for research conducted in non-
U.S. developed countries (Kjellström & Fridlund, 2010), and in the developing world
(Bavdekar, Gogtay, & Wagh, 2008; Myles & Tan, 2003; Sumathipala et al., 2008; Abdur
Rab et al., 2008). Little research has compared RECs between different countries (Klitzman,
2007).
At times, dual approval may be obtained in such collaborative research (Emanuel et al.,
2004; Kass et al., 2003; Shapiro & Meslin, 2001; Varmus & Schacter, 1997), and can be
important, since approval by both a host country REC (which presumably knows the local
conditions and context of the research setting better than the sponsor country REC), and a
sponsor country REC (which may possibly be more familiar with the sponsor country
investigators and REC regulations), can together help assure that the protocol has been
reviewed as thoroughly as possible. In the United States, human subject research funded by
the federal government is subject to 45 CFR 46, which states,
When research covered by this policy takes place in foreign countries, procedures
normally followed in the foreign countries to protect human subjects may differ
from those set forth in this policy…. In these circumstances, if a department or
agency head determines that the procedures prescribed by the institution afford
protections that are at least equivalent to those provided in this policy, the
department or agency head may approve the substitution of the foreign procedures
in lieu of the procedural requirements provided in this policy. (Department of
Health and Human Services, 2005)
Presumably, this statement could thus be interpreted as mandating a review by an REC or its
equivalent. But these regulations leave many questions unaddressed—e.g., concerning
research that is not funded by the U.S. government. It is also unclear if foreign REC review
is required, or if an agency head can just determine that the foreign researchers appear, on
their own, to be following equivalent guidelines. Other countries’ guidelines vary.
Guidelines of the European Union (European Commission Group on Ethics in Science and
New Technologies, 2003), Canada (Interagency Advisory Panel on Research Ethics, 2005),
Japan (Ministry of Health, Labor, and Welfare, 2003), New Zealand (Health Research
Council Ethics Committee, 2005), and the UK (Medical Research Council, 2004) require
dual review. The national guidelines in Uganda recommend it (Uganda National Council on
Science and Technology, 2007), and those in India (Indian Council of Medical Research,
2006) do not specifically mention it at all. Nigerian and Thai guidelines allow local RECs to
accept another institution’s review (National Health Research Ethics Committee, 2007;
Medical Council of Thailand, 2007). Australian guidelines require the researcher to inform
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the Australian REC of the host country’s ethics review process and capacity (National
Health and Medical Council, Australian Health Ethics Committee, 2007).
We have found no studies that examine how often and when such dual approval in fact
occurs. Given what little is known about how and when dual review occurs, an important
first step is to assess how often published journal articles reporting on such research in fact
mention dual REC approval.
In 1997, the International Committee of Medical Journal Editors (ICMJE) revised the
uniform requirements for REC approval reporting in medical journals, and specified that
authors should indicate whether research procedures followed the ethical standards of the
appropriate institutional or national committee on human experimentation (International
Committee of Medical Journal Editors [ICMJE], 1997). Nearly 800 journals are included on
an online list of journals that claim to follow the ICMJE’s uniform requirements for
manuscripts, including many which publish articles on research carried out in developing
countries (ICMJE, 2009). In response to ICMJE recommendations, the rates of reporting
REC approval did seem to improve initially, as illustrated by a study of 103 English-
language journals included in the Abridged Index Medicus, showing that compliance with
REC approval requirements jumped from 45% to 76% between 1995 and 2005, and was
associated with higher impact factors of journals (Rowan-Legg et al., 2009). But, at least in
anesthesiology, compliance rates may vary based on type of study (e.g., clinical trial vs.
observational study), and the specific journal (Matot, Pizov, & Sprung, 1998; Myles & Tan,
2003).
Moreover, studies of articles from the developing world suggest less compliance with these
guidelines than that found in analyses of articles in the developed world. A 2008 study
found that of Sri Lankan research articles, only 38% documented REC/REC approval
(Sumathipala et al., 2008), and of research papers published in two Indian pediatrics
journals, only approximately 30% reported REC/REC approval (Bavdekar, Gogtay, &
Wagh, 2008). Yet, the first of these studies did not explore other factors potentially
associated with reporting of REC approval, such as author affiliations, type of research, or
type of journal; and the second study examined only two journals from the same country,
and failed to distinguish between Indian primary investigators and those not from India.
Importantly, neither study examined the rates of reporting of dual REC approval, when
research was sponsored by one country, but carried out in another.
Thus, we decided to explore how often dual REC approval is mentioned in journal articles
reporting on research conducted in one of four developing world countries, with
involvement of a developed world nation. We also examined what characteristics of the
authors, journal, and study might be associated with differences in reporting of this
approval. We chose to focus on HIV, since its effects are widespread (the pandemic affects
approximately 38.6 million people worldwide), and is a crucial area of medical research in
both developed and developing countries (Joint United Nations Programme on HIV/AIDS,
2006). HIV research also involves vulnerable and stigmatized populations—making
protections of subjects particularly important—and has been the subject of much
controversy (Angell, 1997; Angell, 2000; Lurie & Wolfe, 1997). Of articles reporting on
HIV research in the developing world, we have found that 80% did not mention conflicts of
interest, and 32% did not mention any REC approval (Klitzman et al., 2011; Klitzman et al.,
2010). But for those studies that involve both a developed as well as a developing country,
extremely crucial, separate questions arise that have never been explored—e.g., whether
these studies mention dual review, and if so, how often, which do or do not, what they say,
and what factors are involved. Hence, we have investigated these vital questions here.
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We conducted a search of the Medline database for all articles published in 2007 which met
the following search criteria: (1) HIV research involving human subjects and (2) the
research was sponsored by a developed country, but carried out in one of four developing
countries (India, Thailand, Nigeria, or Uganda). We chose these countries since they have
among the highest HIV prevalence in their respective geographic regions and the largest
numbers of U.S.-sponsored HIV clinical trials (U.S. National Institutes of Health, 2008). We
limited the search to papers with human subjects written in English. From the search, we
included all articles that were available online through our university medical library, which
holds 117,264 serials (Columbia University, 2008). We included only original research
articles of studies involving human subjects, and excluded review articles, meta-analyses,
letters, communications, brief reports, case reports, retrospective chart reviews, news
articles, and data obtained from public databases (i.e., data collected for purposes other than
research, such as state records and national epidemiological surveillance programs). Since
this research did not involve human subjects (i.e., we did not interact with any subjects in
any way), it was exempt from REC review at our institution.
Two research assistants (RAs), closely supervised by the senior author, independently coded
the articles meeting the inclusion criteria. First, they each independently coded a sample of
ten articles consisting of at least two articles from each country. They then developed a
coding manual, and subsequently coded ten more articles independently and compared the
results, revising the manual as necessary. They coded additional sets of ten articles
independently, comparing results and discussing any disagreements (e.g., whether a study
was more than minimal risk) until they reached complete consensus. All articles were then
recoded using the final codebook. The articles were coded for factors in categories related to
ethical characteristics (i.e., mention of informed consent, financial and nonfinancial
compensation, and conflict of interest); study characteristics (i.e., type of intervention; the
study being a clinical trial or not; the study being more than minimal risk or not); study
population (i.e., whether the study involved vulnerable populations [e.g., infants or children,
or individuals with HIV or other medical disorders]); funding characteristics (i.e., whether
the funding source was mentioned, and whether the funding was from industry or not);
authorship characteristics (percent of sponsor authors < 50% or ≥ 50%; country of
corresponding author; and name of sponsor country); and journal characteristics (i.e.,
location of the journal editors, and the journal being affiliated with ICMJE or not).
In this analysis, we chose mention of REC approval (i.e., dual REC approval, single REC
approval, or no REC approval mention) as the primary outcome variable. To explore
potential differences among countries, we assessed rates both among all countries in a four-
way analysis (to see whether, overall, reporting of REC approval varied across countries),
and between countries in two-way analyses (individual country vs. all other countries to see
whether any particular country varied from the others). We used chi-square for these
analyses because one cell (the number of studies from Nigeria that reported single REC
approval) was zero, and we were thus unable to use polytomous regressions, as described
below. To evaluate the associations between article characteristics and mention of REC
approval, we employed both a simple and a multiple polytomous logistic regression analysis
in order to obtain both p-values and odd ratios, indicating the direction of differences that
emerged. Article characteristics that were found associated with mention of REC approval,
with a p-value less than .10 from the simple polytomous regression analyses, were entered
into the multiple polytomous regression model to determine the final predicting model. We
report the odds ratio for the simple polytomous logistic regression analyses, and the adjusted
odds ratio for the multiple polytomous logistic regression analyses and the corresponding p-
values and 95% confidence intervals (CI).
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Of the 590 articles found on Medline searches, 154 (26.1%) met inclusion criteria (i.e., were
sponsored by one country and conducted in another country). Of these 154 articles,
approximately 52% (n = 80) reported REC approval from both host and sponsor countries,
22% (n = 34) reported approval from only one REC, and 26% (n = 40) mentioned no REC
approval. Of the 34 reporting approval from only one REC, 27 mentioned an REC from the
host country, 4 from the sponsor country, and 3 were unknown (i.e., REC approval was
obtained, but the location of the REC was not mentioned).
As shown in Table 1, overall reporting of dual REC approval did not vary significantly by
country. However, articles from Uganda were more likely, and those from India were less
likely, than those from other countries to mention dual REC approval vs. no mention of REC
approval. We also found that there was a trend for articles from Nigeria to be more likely
than articles from other countries to mention dual REC vs. single REC approval.
Table 2 illustrates the associations between type of REC approval (dual, single, or no
mention), and independent variables that reflect ethical and characteristics of the articles,
using a simple polytomous logistic regression analysis.
The simple polytomous logistic regression analysis showed that articles that mentioned dual
REC approval were more likely than those that mentioned only single REC approval to have
≥ 50% sponsor country authors (OR = 5.182, 95% CI = 2.179, 12.324, p = < 0.001); to have
the U.S. as the sponsor country (OR = 2.535, 95% CI = 1.083, 5.933, p = .032); and to have
the corresponding author from a sponsor country (OR = 5.46, 95% CI = 2.13, 14.08, p <
0.001). Articles that reported dual REC approval were more likely than those that did not
mention any REC approval to also mention informed consent (OR = 13.148, 95% CI =
5.117, 33,786, p < 0.001 [i.e., conversely, those articles reporting informed consent were 13
times more likely to mention dual rather than no REC approval]); funding source (OR =
3.000, 95% CI = 1.164, 7.732, p = .023); have ≥50% authors from sponsor country (OR =
2.739, 95% CI = 1.247, 6.018, p = .012); appear in journals that had adopted ICMJE
guidelines (OR = 7.667, 95% CI = 1.707, 34.431, p = .008); and involve biomedical (vs.
psychosocial) research (OR = 3.65, 95% CI =1.64, 8.13, p = .001).
We then simultaneously entered all the variables that were found above to have associations
that were significant or trends into a multiple polytomous regression analysis. As shown in
Table 3, findings suggest that articles that mentioned dual REC were also more likely than
those that mentioned single REC approval to have ≥ 50% sponsor country authors (Adj. OR
= 4.152, 95% CI = 1.424, 12.109, p = .009), and the U.S. as the sponsor country (Adj. OR =
3.407, 95% CI = 1.220, 9.515, p = .019), and to have a corresponding author from a sponsor
country (Adj. OR = 3.41, 95% CI = 1.05, 11.11, p = .042). Articles that reported dual REC
approval were more likely than those that mentioned no REC review to mention informed
consent (Adj. OR = 17.865, 95% CI = 5.628, 56.612, p < 0.001) and funding source (Adj.
OR = 6.447, 95% CI = 1.814, 22.921, p = .004), to involve biomedical research (Adj. OR =
3.21, 95% CI = 1.12, 9.26, p =.032), and to have been published in journals that adopted
ICMJE guidelines (Adj. OR = 7.457, 95% CI = 1.188, 46.825, p = .032).
Discussion
These data indicate that of articles we examined reporting human subject research sponsored
by a developed country, but carried out in the developing world, only about half reported
REC/REC approval from both countries. Of the articles that did not mention dual REC
approval (i.e., mentioned single or no REC approval), approximately 41% had a U.S.
sponsor, 40% had a sponsor-country corresponding author, and 34% had mostly sponsor-
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country authors. Studies mentioning dual REC approval were also more likely than studies
that mentioned single or no REC approval to be biomedical (vs. psychosocial), have more
authors from the sponsor country, and appear in journals affiliated with the ICMJE, and, as a
trend, have U.S. sponsorship. Of note, significant differences did not arise regarding the type
of study (clinical trial or not), degree of risk in the study, or use of vulnerable populations.
Articles from Uganda were more likely, and those from India were less likely, to mention
dual rather than no REC approval.
These data suggest that both ethical and logistical factors are associated with whether
articles report dual REC approval or not. Dual approval was associated with mention of
other ethical features of articles (e.g., informed consent, nonfinancial benefits to
participants, and conflicts of interest). Hence, some authors may simply be more likely than
others to report ethical characteristics of their research in general. Indeed, mention of
informed consent was highly significant in the multiple polytomous regression model,
controlling for other logistical aspects of the research, when comparing mention of dual vs.
no REC approval. Thus, authors’ attention to these ethical issues appears independent of
other characteristics of these authors or their research (e.g., type of research, location of
corresponding author, etc.).
Several of the factors associated with the mention of dual REC appeared to be more
logistical, reflecting structural variables—e.g., different regulatory environments in which
researchers worked. Specifically, mention of dual REC approval was associated with the
location of the corresponding author, the percentage of sponsor-country authors (which may
suggest other aspects of the type and extent of the involvement of the sponsoring country),
and the sponsor country being the U.S. (vs. elsewhere). These three variables all appeared to
be significant in our model, when controlling for each other, suggesting that they each
contributed independently to the likelihood that an article will report dual REC approval.
Future research can explore these phenomena more fully. For instance, the percent of
sponsor authors may in part reflect the likelihood that at least one of these authors’
institutions will require REC approval that may then get documented in the paper.
The type of research itself (biomedical vs. psychosocial) may reflect ethical and logistical
issues, as well as other issues. Biomedical research may involve higher risks to participants
—and thus lead to researchers having more funding and obtaining and reporting dual
approval. This factor was highly significant in comparisons of mention of dual vs. no REC
approval. Yet, level of risk did not appear to be significantly associated with mention of dual
REC approval vs. single or no mention of REC approval. However, studies may entail other
kinds of risk that were not described in the published paper, and for which we thus did not
code. The relatively high rates of nonreporting of dual REC approval is disturbing because
REC approval from both host and sponsor countries may increase the likelihood that a
review has occurred that is thorough, and aware as possible of the local context to help avoid
the potential of researchers adopting lower standards.
The reporting differences that emerge between countries highlight, in part, the regulations of
individual countries. The sponsor countries other than the U.S. were those in the European
Union, Japan, Canada, and Australia. Regulatory guidelines among both these hosts and
these sponsor countries range widely concerning dual REC approval, from requiring it, to
recommending it, to not mentioning it. Yet articles involving any one of these countries vary
widely in whether they mention dual, single, or no REC approval. No government
regulations mention reporting of REC approval in published articles.
The fact that articles from India are less likely than those from other countries to report dual
rather than no REC approval may reflect in part the fact that India’s guidelines do not
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specifically mention dual review. But published guidelines alone do not wholly predict
findings. While guidelines in the U.S. and in several other developed countries (e.g., the EU
and Canada) appear similar, studies sponsored by the U.S. were more likely than those
sponsored by other developed countries to report dual rather than single REC approval and,
as a trend, to report dual rather than no REC approval. Hence, other factors—e.g., whether,
and to what degree, guidelines are monitored, enforced, and followed—can play critical
roles. Future research can probe in further detail when and how guidelines in each country
are in fact monitored, enforced, and followed.
Of note, the national guidelines outlined here appear to have been in place by 2007, though
Japan required dual REC approval only in 2008, and Uganda and Australia revised their
regulations slightly in 2007, making it difficult, if not impossible, to know what exact
guidelines researchers knew and/or followed when they conducted, wrote, and published
their articles. Again, the present data raise several critical issues that future research can
examine in more detail concerning whether, to what degree, how, and why authors and
editors follow specific guidelines or not. Future investigations can also focus on articles
from each non-U.S. sponsoring country separately.
The finding that single (vs. dual) REC approval was associated with investigators from
sponsor countries other than the U.S. is noteworthy and surprising, since anecdotally, not
obtaining optimal REC approval is often assumed to be due to a deficiency in the developing
(not the developed) country.
It is possible that articles that did not mention dual or single REC approval nonetheless
obtained it. We did not contact the authors of these articles to determine whether they in fact
did so, but future research could pursue this possibility, contact authors directly, interview
them (e.g., about whether, how, and why they made decisions concerning obtaining and
reporting REC approval), and examine protocols themselves.
Research may also be exempt from REC review—e.g., if it analyzes de-identified data
without direct contact with research participants; however, we reviewed the 72 articles that
reported single or no REC approval, and found one only study with an explicit reference that
the data were de-identified. Moreover, none of these studies reported that they were exempt
from REC review. Thus, exemption from review does not appear to account for the
relatively low rates here of reporting REC approval.
This study has several potential limitations. We only examined journals available online.
Therefore, not all journals may have been available. Yet, even among these available
journals, we still found relatively high rates of failure to mention dual REC approval. The
sample size was sufficiently large to reach significance for several analyses, but larger
sample sizes can permit assessment of additional variables, and can be pursued in future
research.
Best Practices
Authors from developed countries conducting research in developing countries should take
particular care to seek dual review and to so state in the publication of the research, as it has
special significance for understanding sensitivity to local cultures and norms.
Research Agenda
Subsequent studies can also contact RECs directly to assess how often, where, and why they
require dual REC approval, and what problems or discrepancies may emerge between the
two RECs. Additional research can also probe impediments that might exist to adhering to
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regulations in various countries, and the ways that differing regulations may account further
for variations found here.
Educational Implications
Researchers, including senior and junior researchers and trainees, in both the developing and
the developed world (i.e., when collaborating with researchers abroad) need to be educated
concerning the importance of obtaining and reporting dual REC approval in various
situations.
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